Page last updated: 2024-09-04

atazanavir sulfate and Dyslipidemia

atazanavir sulfate has been researched along with Dyslipidemia in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (56.25)29.6817
2010's5 (31.25)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS1
Hatleberg, CI; Ryom, L; Sabin, C1
Chen, JS; DiMeglio, LA; Geffner, ME; Jacobson, D; Jao, J; Karalius, B; McFarland, EJ; Miller, TL; Mirza, A; Patel, K; Silio, M; Van Dyke, RB; Yu, W1
Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Ferraris, L; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Minisci, D; Molinari, L; Riva, A; Rizzardini, G1
Kiertiburanakul, S; Numthavej, P; Puangpetch, A; Sukasem, C; Thakkinstian, A; Wongprikorn, A1
Roca, B1
Cope, D; Iskander, E; Mikhail, N1
Gatell, JM; Zamora, L1
Boix, V; Merino, E; Portilla, J; Reus, S1
Martínez Chamorro, E1
González, M; Palacios, R; Ruiz, J; Santos, J1
Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S1
Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW1
Adams-Huet, B; Boonyavarakul, A; Dinges, W; Garg, A; Jacob, K; Peterson, D; Quittner, C; Shah, M; Tierney, K1
Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Herrington, JD; Maclayton, DO; Nguyen, ST; Payne, KD; Rahman, AP; Rodriguez-Barradas, MC1
Bedimo, R; Busti, AJ; Hardin, DS; Margolis, DM1

Reviews

6 review(s) available for atazanavir sulfate and Dyslipidemia

ArticleYear
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
    Expert opinion on drug safety, 2021, Volume: 20, Issue:11

    Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic

2021
Pharmacogenomics of antiretrovirals.
    Recent patents on anti-infective drug discovery, 2008, Volume: 3, Issue:2

    Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir

2008
[Efficacy of atazanavir in simplification regimens].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 17

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome

2008
[Efficacy of atazanavir in rescue therapy].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Dyslipidemias; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Oligopeptides; Patient Compliance; Point Mutation; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load

2008
[Lipid profile of atazanavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 17

    Topics: Adipocytes; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Cells, Cultured; Cholesterol; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Glucose; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Multicenter Studies as Topic; Oligopeptides; Pyridines; Risk Factors; Salvage Therapy; Triglycerides

2008
[Adverse effects of atazanavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 17

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbohydrate Metabolism; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Gastrointestinal Diseases; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Hyperinsulinism; Insulin Resistance; Oligopeptides; Pyridines; Urolithiasis

2008

Trials

5 trial(s) available for atazanavir sulfate and Dyslipidemia

ArticleYear
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
    Antimicrobial agents and chemotherapy, 2020, 08-20, Volume: 64, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome

2020
Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Adult; Atazanavir Sulfate; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, LDL; Male; Middle Aged; Quinolines; Ritonavir; Treatment Outcome; Triglycerides

2016
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
    HIV medicine, 2011, Volume: 12, Issue:6

    Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load

2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
    HIV medicine, 2011, Volume: 12, Issue:10

    Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome

2011
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2008, Volume: 56, Issue:2

    Topics: Adult; Aged; Atazanavir Sulfate; Body Composition; Dyslipidemias; HIV Infections; HIV Protease Inhibitors; Humans; Insulin Resistance; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Treatment Outcome; Triglycerides

2008

Other Studies

5 other study(ies) available for atazanavir sulfate and Dyslipidemia

ArticleYear
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
    HIV medicine, 2018, Volume: 19, Issue:3

    Topics: Adolescent; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Longitudinal Studies; Male; Ritonavir; Viral Load; Young Adult

2018
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Nephrolithiasis; Ritonavir; Viral Load

2015
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
    Current drug safety, 2009, Volume: 4, Issue:2

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir

2009
The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy.
    HIV medicine, 2005, Volume: 6, Issue:4

    Topics: Adult; Atazanavir Sulfate; Cholesterol; Diet; Dietary Fiber; Dietary Proteins; Dyslipidemias; Exercise; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Pyridines; Smoking; Trans Fatty Acids; Triglycerides

2005
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Pharmacotherapy, 2008, Volume: 28, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Mass Index; Body Weight; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir

2008